| GlaxoSmithKline AG - Havrix 1440, Injektionssuspension | | 00558 | | 02 | | Havrix 1440 | | Injektionssuspension | | J07BC02 | | Hepatitis A, Inactivated, Whole Virus | | 03.09.1993 | | |
| | Composition | | Vaccinum adsorbatum: hepatitis-A-virus inactivatus (HM175) 1440 U. corresp. proteina max. 0.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.5 mg, aminoacida cum phenylalaninum 166 µg, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, kalii chloridum, polysorbatum 20, aqua ad iniectabile, ad suspensionem pro 1 ml corresp. natrium max. 3.6 mg et kalium max. 0.5 mg, residui: neomycini sulfas. | | Packungsbestandteile | | Injection suspension | | | | | | | | Active Agent | Dose | additional_information |
|---|
| Hepatitis-A-Virus Inactivatus (Hm175) | 1440 U/ml correspond Protein 0.4 µg/ml | Vaccinum adsorbatum |
| | BAG: Active Agent | Dose |
|---|
| Vaccinum Hepatitidis a Inactivatum Adsorbatum | 1440 U |
| | | | Inactive agents | Dose |
|---|
| Aluminii Hydroxidum Hydricum ad Adsorptionem | | | Aminoacida cum Phenylalaninum | 166 µg/ml | | Disodium Phosphate | | | Potassium Chloride | | | Potassium Dihydrogenophosphate | | | Sodium Chloride | | | Polysorbatum 20 | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | 31.84 | 51.05 | B | SL | No |
|
|
